FDA Biosimilar Naming Proposal Pits Providers, Patients Against Insurers, Pharmacies

Suffix-based, distinguishable names cheered by physicians and patient advocacy groups as enhancing patient safety; payers and pharmacists object, saying plan adds unneeded complexity and will require expensive overhauls in databases and operating systems.